Neurotrophic peptidomimetic
P021
P021 is a CNTF-derived peptide studied in mice and rats; a review by its developers reports a plasma half-life of more than 3 hours, and no human trial was identified.1
P021 after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- P021
- Symbol
- P21
- Family
- Cognitive and sleep peptides
- Parts
- 13
- References
- 7
- Checked
- Last reviewed . Sources are listed below.
Overview
P021 is described by its developers as a neurotrophic and neurogenic peptide derived from the most active region of ciliary neurotrophic factor (CNTF).2 Baazaoui and Iqbal (Alzheimer's Research & Therapy, 2017) give its formula as Ac-DGGLAG-NH2 with a molecular weight of 578.3, made by adding adamantylated glycine at the C-terminus of a CNTF tetrapeptide (residues 148 to 151).2 The research cited here is in cell cultures, mice and rats; the app lists the compound as a neurotrophic peptidomimetic and grades its evidence as limited.7 The app's notes call the compound preclinical only and describe its pharmacokinetic values as nominal and extrapolated rather than validated in people. Every paper cited here has Khalid Iqbal as an author, and the competing-interest statements in three of them say he holds patents on P021 or related peptide mimetics.1,6,7
How it works
Kazim and Iqbal (Molecular Neurodegeneration, 2016) draw the proposed mechanism as P021 increasing BDNF expression, which acts through the TrkB-PI3K-AKT pathway to inhibit GSK3β by phosphorylation at Ser9.1 The same figure legend states that GSK3β is a major tau kinase.1 Kazim and colleagues (Scientific Reports, 2017) cite earlier work from the group in which P021 acted by "dose-dependent competitive inhibition of LIF activity towards LIF/CNTF receptor".6 Baazaoui and Iqbal write that the adamantylated glycine was added "to increase its blood-brain barrier permeability and decrease its degradation by exopeptidases".2 Mottolese and colleagues (Journal of Neurodevelopmental Disorders, 2024) state that "the exact mechanism of action of P021 associated with neuroprotection and neuroplastic changes is unknown".7 In that paper P021 did not raise BDNF in Cdkl5 knockout mice, and the authors cite earlier findings that it does not raise BDNF in the hippocampus of wild-type mice.7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 80%
- Typical dose
- 1–5 mg/day
- Route
- Oral
- Time to peak
- ~1 h
Sources in this part
The table sets the app's figures beside what the papers report; the papers give stability tests in plasma and artificial gut fluids and a permeability finding in mice, and no figure from people.
| Parameter | App's figure | Reported in the papers |
|---|---|---|
| Half-life | ~2 h | Plasma half-life of >3 h, stated in a review by the compound's developers without a species or method1 |
| Bioavailability | 80% | Described as orally bioavailable by the developers; no percentage figure appears in the papers cited6 |
| Time to peak | ~1 h | No time to peak is reported in the seven papers cited here |
| Stability in gut fluids | Not in the app | About 100% stability in intestinal fluid over 120 min in Baazaoui and Iqbal2; the group's 2016 review gives stability of more than 95 % in artificial intestinal fluid up to 2 h and more than 90 % in artificial gastric juice up to 30 min1 |
| Brain entry | Not in the app | Reported as blood–brain barrier permeable in adult C57Bl/6 mice, in studies by a commercial service described in a prior paper6 |
The app's half-life of 2 hours is lower than the more-than-3-hour plasma half-life the developers report, and the app's own notes say its values are nominal.1 Kazim and colleagues (2017) say plasma and gut-fluid stability tests were done at EVER NeuroPharma GmbH, Austria, a company that also appears among the funders of the group's work.6
Human studies
Sources in this part
No controlled trial in people was identified in PubMed or ClinicalTrials.gov in searches for P021. Baazaoui and Iqbal state that "No human research subjects were involved in this study" and that "more extensive pharmacokinetic and pharmacodynamic studies will be required before its safety and efficacy in AD patients can be tested".2 The 2024 paper's competing-interest statement says its co-author Iqbal "is in the process of developing P021 as a therapeutic drug".7
Studies in animals
The table lists the animal studies read, with the main result and the dose or feeding schedule each reports.
| Study and year | Design | Animals | Dose and length | Main result |
|---|---|---|---|---|
| Kazim and colleagues, Neurobiology of Disease, 20143 | Chronic oral treatment against a vehicle diet in a triple transgenic Alzheimer's model | Female 3xTg-AD and wild-type mice, starting at 9 to 10 months of age | P021 or vehicle diet for 12 months; the dose is not given in the PubMed record | Reduced tau hyperphosphorylation; Aβ effect limited to lower soluble Aβ and a trend in plaque load in CA13 |
| Bolognin and colleagues, Neurobiology of Aging, 20144 | Chronic oral administration in aged rats | Fisher rats aged 22 to 24 months | Oral administration; dose and length are not given in the PubMed record | Reduced the age-dependent decline in learning and memory; neurogenesis deficit inhibited; lower hippocampal myoinositol4 |
| Baazaoui and Iqbal, Alzheimer's Research & Therapy, 20172 | Diet started before overt pathology, against a vehicle diet | Female wild-type (n = 41), 3xTg-AD vehicle (n = 35) and 3xTg-AD P021 (n = 32) mice | 60 nmol/g feed from 3 months of age, continued to 21 months | Rescued dendritic and synaptic deficits, neurogenesis and cognitive impairment on the authors' tests2 |
| Wei and colleagues, Alzheimer's Research & Therapy, 20205 | Maternal diet from gestation to weaning, then follow-up to 22 months | 3xTg-AD and wild-type female offspring | P021 diet to mothers from embryonic day 8 to postnatal day 21 | Rescued cognitive deficits at 4 months; lower tau hyperphosphorylation; lower Aβ plaque load at 22 months; anxiety-like behavior not relieved in one maze test5 |
| Kazim and colleagues, Scientific Reports, 20176 | Maternal diet from gestation to weaning in a Down syndrome model | Ts65Dn mice | 200 nmoles/g diet to dams from embryonic day 8 to postnatal day 21 | Rescued the delay in surface righting, cliff aversion and ear twitch in pups, and memory impairment in adults; a trend only for negative geotaxis (p = 0.09); no significant effect on anxiety-like behavior in the elevated plus maze6 |
| Mottolese and colleagues, Journal of Neurodevelopmental Disorders, 20247 | Cell culture plus oral diet and intraperitoneal injection in a CDKL5 deficiency model | SH-CDKL5-KO cells and male Cdkl5 knockout mice | 60 nmol/g diet for 70 days; 750 nmol per mouse intraperitoneally daily for 30 days | Restored deficits in cells; in mice no BDNF increase, no improvement in neuroanatomical defects and limited behavioral benefit7 |
Deeper analysis: prevention study in 3xTg-AD mice (Baazaoui and Iqbal, 2017)
The study fed female 3xTg-AD mice a P021 diet from 3 months of age, 6 to 9 months before overt amyloid or tau pathology, and compared them with vehicle-fed 3xTg-AD mice and vehicle-fed wild-type mice.2 Behavior was tested in separate animals from those used for tissue analysis, at 9 months of treatment (Morris water maze) and 15 to 16 months (object location task).2 The authors calculated an average intake of 162 nmol P021 per mouse per day.2 At 9 months, doublecortin-positive cells were reduced in vehicle-fed 3xTg-AD mice against wild-type (p = 0.0009), and the authors report that "the level of neurogenesis was rescued to more than the level in the WT group with P021".2 In the water maze probe trials, the P021 group's time in the target quadrant differed from vehicle-fed 3xTg-AD mice in the first probe trial (p < 0.01), but the number of platform-location crossings in that trial showed "no significant difference between the three groups".2 In the neophobia test, P021-treated mice "spent significantly more time exploring the novel object compared to the other two groups".2 Of side effects, the authors state that "P021 did not show any severe side effects or safety issues" over almost 2 years.2 Their stated limitations include that the model "does not recapitulate the mechanism and full comprehensive neuropathology of human AD", that only female mice were used, and that the wild-type mice "were not ideal littermate controls to the transgenic mice".2 Funding was in part from an Alzheimer's Association Zenith Award to Iqbal and a graduate fellowship, and the authors declare no competing interests.2 Iqbal's U.S. patents on CNTF small-molecule peptide mimetics are declared in the group's 2016 review, which this paper's no-competing-interests statement does not mention.1 The same group's Kazim and colleagues (2014) report that 12 months of oral P021 in older 3xTg-AD mice reduced tau hyperphosphorylation, and that the effect on Aβ "was limited to a significant decrease in soluble Aβ levels and a trend towards reduction in Aβ plaque load in CA1 region of hippocampus".3 Those authors attribute the effect "probably" to a BDNF-mediated decrease in GSK3β activity; their funding and competing-interest statements are not quoted here.3
Deeper analysis: Cdkl5 knockout model (Mottolese and colleagues, 2024)
The study from the University of Bologna with Iqbal as co-author tested P021 in a human neuronal cell model of CDKL5 deficiency and in Cdkl5 knockout mice.7 In cells, "P021 treatment was effective in restoring neuronal proliferation, survival, and maturation deficits, as well as alterations in the GSK3β signaling pathway".7 In mice, oral P021 began at postnatal day 21 and ran 70 days; in a separate experiment, 4-month-old male Cdkl5 knockout mice were given a higher intraperitoneal dose of 750 nmol per mouse daily for 30 days.7 The authors write that "Even at this higher dose, P021 was not effective in improving neuroanatomical defects in Cdkl5 KO mice".7 They add that treatment "may help brain development/function under some abnormal brain conditions such as Alzheimer’s disease (AD) and Down syndrome (DS)" but not in CDKL5 deficiency, while noting they "cannot exclude the possibility that gender or background specific differences could impact the results".7 Funding came from an Italian parent association for CDKL5 and Italy's Ministry of University and Research; the competing-interest statement lists Iqbal as cofounder and Chief Scientific Officer of Phanes Biotech Inc., with patents on P021.7
Deeper analysis: prenatal and early postnatal diet studies
Wei and colleagues (Alzheimer's Research & Therapy, 2020) fed P021 to pregnant and nursing 3xTg-AD and wild-type mothers, and followed the female offspring to 22 months.5 The authors name as limitations that the study "lacks information on the level of the compound that reached the brain in fetuses and pups" and that it "did not determine whether the beneficial effect of the P021 treatment is due to this treatment during the prenatal or the postnatal period, or both".5 That study was supported in part by the New York State Office for People With Developmental Disabilities and the State Scholarship Fund of China, and its authors declare no competing interests.5 Kazim and colleagues (Scientific Reports, 2017) used a higher diet concentration of 200 nmoles/g in a Down syndrome mouse model, and the authors report grants from the Alzheimer's Association, the Alzheimer's Drug Discovery Foundation and EVER NeuroPharma GmbH.6
Doses reported in studies and on labels
No label for P021 was identified, and none of the papers cited reports a dose given to a person; the doses below are animal doses.
| Study | Animals | Route | Dose | Length |
|---|---|---|---|---|
| Baazaoui and Iqbal 20172 | Female 3xTg-AD mice | In the diet | 60 nmol/g feed, about 162 nmol per mouse per day by the authors' calculation | From 3 months of age, around 18 months |
| Wei and colleagues 20205 | Pregnant and nursing 3xTg-AD and wild-type mice | In the diet | 60 nmol peptide/g formulated diet | Embryonic day 8 to postnatal day 21 |
| Kazim and colleagues 20176 | Ts65Dn dams and pups | In the diet | 200 nmoles/g diet | Embryonic day 8 to postnatal day 21 |
| Mottolese and colleagues 2024, oral7 | Cdkl5 knockout male mice | In the diet | 60 nmol peptide/g formulated diet | 70 days from postnatal day 21 |
| Mottolese and colleagues 2024, injection7 | Cdkl5 knockout male mice, 4 months old | Intraperitoneal | 750 nmol per mouse in saline, daily | 30 days |
| Bolognin and colleagues 20144 | Aged Fisher rats | Oral gavage | Not given in the PubMed record | Not given in the PubMed record |
The app lists a typical dose of 1 to 5 mg/day by the oral route, and none of the papers cited reports a figure in mg/day for any species.
Side effects reported
Sources in this part
Baazaoui and Iqbal report that treatment for around 18 months "did not show any weight loss, tumors, or signs of pain in 3 × Tg-AD mice", a comparison they draw with CNTF itself, which causes "anorexia, severe cramps, and muscle pain".2 Kazim and Iqbal write that "Up to 1 year of P021 administration did not induce any adverse effect in 3xTg-AD mice or in wild type control".1 These are the developers' observations in mice; the papers cited here do not report a toxicology study, and no safety data from people were identified.2
Regulatory and anti-doping status
Sources in this part
No DailyMed drug label was identified in a search for P021, and the 2024 paper's competing-interest statement says Iqbal is in the process of developing P021 as a therapeutic drug.7
What is not known
- Whether P021 reaches the brain, or has any effect, in people: the papers report no human pharmacokinetic, dose or safety data.2
- How much of the compound reaches the brain at different stages of development; Wei and colleagues say their study lacked this information.5
- Which mechanism accounts for the effects: Mottolese and colleagues say the exact mechanism "is unknown".7
- Why the Alzheimer's and Down syndrome mouse results were not matched in the Cdkl5 model: Mottolese and colleagues say they cannot exclude gender or background specific differences as an influence on the results.7
- Whether results from groups other than the developers' collaborators would agree: every paper cited includes Iqbal as an author.1
Frequently asked questions
What is the half-life of P021?
Has P021 been tested in humans?
No controlled trial in people was identified in PubMed or ClinicalTrials.gov. The published work is in cells, mice and rats.7
What is P021?
P021 is a peptide with the formula Ac-DGGLAG-NH2, derived from ciliary neurotrophic factor.2
Is P021 approved as a medicine?
No DailyMed label was identified in a search for P021.
Does P021 cross the blood-brain barrier?
The developers report that it does in mice, citing studies by a commercial service.6 No measurement in people was identified.
Is P021 orally active?
What did P021 do in Alzheimer's disease mouse models?
Did P021 work in every animal model tested?
No: in Cdkl5 knockout mice P021 failed to increase BDNF levels and did not improve neuroanatomical defects.7
What side effects has P021 shown?
In mice the developers report no severe side effects or safety issues over almost 2 years, and no weight loss, tumors or signs of pain.2 No safety data from people were identified.
Guides, tools and comparisons
References
- Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease. Mol Neurodegener 2016. PMID 27400746
- Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther 2017. PMID 28655344
- Kazim SF, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2014. PMID 25046994
- Bolognin S, et al. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging 2014. PMID 24702821
- Wei W, et al. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimers Res Ther 2020. PMID 32854771
- Kazim SF, et al. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep 2017. PMID 28368015
- Mottolese N, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord 2024. PMID 39592934